X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (223) 223
humans (213) 213
azd6244 arry-142886 (168) 168
oncology (162) 162
animals (91) 91
cancer (84) 84
melanoma (74) 74
cell line, tumor (73) 73
mutation (71) 71
female (70) 70
inhibitor azd6244 arry-142886 (59) 59
selumetinib (58) 58
mice (55) 55
open-label (54) 54
protein kinase inhibitors - pharmacology (54) 54
arry-142886 (51) 51
signal transduction - drug effects (50) 50
phase-ii (48) 48
antineoplastic agents - pharmacology (47) 47
male (47) 47
benzimidazoles - pharmacology (44) 44
mek (43) 43
melanoma - drug therapy (43) 43
pharmacology & pharmacy (43) 43
apoptosis (42) 42
article (42) 42
braf (42) 42
activation (40) 40
map kinase signaling system - drug effects (40) 40
mitogen-activated protein kinase kinases - antagonists & inhibitors (39) 39
kinases (38) 38
protein kinase inhibitors - therapeutic use (38) 38
cell biology (37) 37
tumors (37) 37
mek inhibitor (36) 36
neoplasms - drug therapy (36) 36
cell proliferation - drug effects (35) 35
middle aged (35) 35
research (35) 35
antineoplastic agents - therapeutic use (34) 34
b-raf (34) 34
proto-oncogene proteins b-raf - genetics (34) 34
xenograft model antitumor assays (34) 34
acquired-resistance (33) 33
apoptosis - drug effects (33) 33
in-vivo (33) 33
metastatic melanoma (33) 33
pathway (33) 33
mutations (32) 32
oral mek inhibitor (32) 32
map kinase kinase 1 - antagonists & inhibitors (31) 31
melanoma - genetics (31) 31
signal-regulated kinase (31) 31
aged (30) 30
benzimidazoles - administration & dosage (30) 30
care and treatment (30) 30
phase-i (29) 29
azd6244 (28) 28
adult (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
chemotherapy (27) 27
phosphorylation (27) 27
biochemistry & molecular biology (26) 26
map kinase kinase kinases - antagonists & inhibitors (26) 26
resistance (26) 26
cell lung-cancer (25) 25
growth (25) 25
kras (25) 25
signal transduction (25) 25
cells (24) 24
health aspects (24) 24
map kinase kinase 2 - antagonists & inhibitors (24) 24
genetic aspects (23) 23
mice, nude (23) 23
ras proteins - genetics (23) 23
melanoma - pathology (22) 22
neoplasms (22) 22
protein kinase inhibitors - administration & dosage (22) 22
proto-oncogene proteins - genetics (22) 22
targeted therapy (22) 22
antitumor-activity (20) 20
colorectal neoplasms - drug therapy (20) 20
drug therapy (20) 20
extracellular signal-regulated map kinases - antagonists & inhibitors (20) 20
kinase kinase-1/2 inhibitor (20) 20
map kinase (20) 20
molecular targeted therapy (20) 20
multicenter (20) 20
proteins (20) 20
proto-oncogene proteins c-akt - metabolism (20) 20
raf (20) 20
ras (20) 20
carcinoma, non-small-cell lung - drug therapy (19) 19
clinical trials (19) 19
drug resistance, neoplasm (19) 19
extracellular signal-regulated map kinases - metabolism (19) 19
lung neoplasms - drug therapy (19) 19
melanoma - metabolism (19) 19
pharmacology (19) 19
proto-oncogene proteins b-raf - antagonists & inhibitors (19) 19
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 03/2011, Volume 10, Issue 3, pp. 385 - 394
The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer. This pathway consists of... 
CPG ISLAND METHYLATION | SERRATED ADENOMAS | ONCOLOGY | BRAF MUTATION | MELANOCORTIN-1 RECEPTOR | NECROSIS-FACTOR-ALPHA | B-RAF | MC1R VARIANTS | RET/PTC REARRANGEMENTS | AZD6244 ARRY-142886 | DEPENDENT ACTIVATION
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2012, Volume 55, Issue 10, pp. 4594 - 4604
Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered.... 
POTENT | CHEMISTRY, MEDICINAL | RECOGNITION | PATHWAY | RAF | AZD6244 ARRY-142886 | HYDROGEN-BONDS
Journal Article
International Journal of Oncology, ISSN 1019-6439, 07/2011, Volume 39, Issue 1, pp. 23 - 31
The MAPK pathway is one of the most important pathways for novel anticancer drug development. We performed high-throughput screening for compounds that induce... 
JTP-74057 | Antitumor activity | MEK | GSK1120212 | PI3K/Akt | HISTONE DEACETYLASE INHIBITOR | KINASE PATHWAY | PANCREATIC-CANCER | CYCLE ARREST | BRAF | COMBINATION | BREAST | GENE | ONCOLOGY | antitumor activity | MUTATIONS | AZD6244 ARRY-142886
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 12/2016, Volume 27, Issue 12, pp. 2210 - 2215
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 38 - 47
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2011, Volume 17, Issue 5, pp. 989 - 1000
Journal Article
Journal of Hepatology, ISSN 0168-8278, 11/2018, Volume 69, Issue 5, pp. 1057 - 1065
Treatment of liver cancer remains challenging because of a paucity of drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is... 
Hepatocellular carcinoma | CRISPR screen | MAPK1 | Sorafenib | ACTIVATED PROTEIN-KINASE | PHASE IB | AZD6244 | ARRY-142886 | REFAMETINIB BAY 86-9766 | COLON-CANCER | HEPATOCELLULAR-CARCINOMA | RESISTANCE | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal Article
Journal Article